By Tom Whitfield

Medscape has published a clinical feature titled "Optimizing Topical Therapy for Atopic Dermatitis," aimed at dermatologists and primary-care prescribers managing the U.S.'s most common chronic eczema.

The piece lands as the topical armamentarium for atopic dermatitis (AD) continues to expand. For decades, treatment centered on topical corticosteroids by potency class, with the calcineurin inhibitors tacrolimus (Protopic, 2000) and pimecrolimus (Elidel, 2001) added as steroid-sparing options for face, neck, and intertriginous sites.

What changed the field?

Two non-steroidal topicals won FDA approval for AD in the past decade. Pfizer's crisaborole (Eucrisa) 2% ointment, a PDE4 inhibitor, cleared in December 2016 for mild-to-moderate disease in patients 3 months and older. Five years later, in September 2021, the FDA approved Incyte's ruxolitinib cream 1.5% (Opzelura) — a topical JAK inhibitor — for short-term treatment of mild-to-moderate AD in patients 12 and older, the first JAK inhibitor cleared for the indication. Opzelura later picked up a vitiligo repigmentation indication, a second FDA nod that reshaped payer discussions.

What's still unsettled?

Medscape's published synopsis does not detail the article's format or contributing faculty, leaving readers to weigh whether the guidance rests on peer-reviewed review, expert opinion, or case-based discussion. The headline signals a focus on selection, sequencing, and adherence, but the available excerpt stops short of prescribing algorithms or payer-access specifics.

Why does optimization matter now?

Topical therapy remains first-line for the majority of AD patients, even after Regeneron-Sanofi's dupilumab (Dupixent) and other systemic biologics reshaped moderate-to-severe disease management starting in March 2017. Choosing the right vehicle, potency, and quantity per body surface area — and counseling caregivers past steroid phobia — drives adherence in a disease most patients carry for years, often beginning in infancy.

Steroid phobia has been a documented barrier across the AD space. That dynamic opened commercial room for non-steroidal agents, though payer prior-authorization workflows have constrained real-world access to the newer topicals since Opzelura's 2021 launch.

What else is in the pipeline?

Dermavant's tapinarof cream 1%, an aryl hydrocarbon receptor agonist already FDA-approved for plaque psoriasis as Vtama (May 2022), sits under late-stage FDA review for atopic dermatitis. A green light would add another non-steroidal option to a category that has thickened since crisaborole arrived.

Sanofi-Regeneron's dupilumab, an IL-4/IL-13 inhibitor first approved for moderate-to-severe AD in March 2017, continues to anchor the systemic end of the treatment ladder. Its commercial run has, in turn, pushed topical manufacturers to differentiate on speed of action, body-surface coverage, and pediatric labeling — the kinds of details a clinical-optimization feature should address.

Dermatologists awaiting the full Medscape feature will be looking for concrete tapering protocols, vehicle-selection guidance, and any head-to-head comparisons among crisaborole, ruxolitinib, and the next wave of non-steroidal agents — details the headline promises but the available synopsis does not deliver.